474 related articles for article (PubMed ID: 17256802)
1. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
[TBL] [Abstract][Full Text] [Related]
2. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties.
Liu BL; Robinson M; Han ZQ; Branston RH; English C; Reay P; McGrath Y; Thomas SK; Thornton M; Bullock P; Love CA; Coffin RS
Gene Ther; 2003 Feb; 10(4):292-303. PubMed ID: 12595888
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
4. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
5. Enhanced therapeutic efficacy of oncolytic herpes vector G207 against human non-small cell lung cancer--expression of an RNA-binding protein, Musashi1, as a marker for the tailored gene therapy.
Kanai R; Eguchi K; Takahashi M; Goldman S; Okano H; Kawase T; Yazaki T
J Gene Med; 2006 Nov; 8(11):1329-40. PubMed ID: 16955534
[TBL] [Abstract][Full Text] [Related]
6. Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters.
Ebara S; Shimura S; Nasu Y; Kaku H; Kumon H; Yang G; Wang J; Timme TL; Aguilar-Cordova E; Thompson TC
Prostate Cancer Prostatic Dis; 2002; 5(4):316-25. PubMed ID: 12627218
[TBL] [Abstract][Full Text] [Related]
7. A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus.
Fu X; Meng F; Tao L; Jin A; Zhang X
Gene Ther; 2003 Aug; 10(17):1458-64. PubMed ID: 12900760
[TBL] [Abstract][Full Text] [Related]
8. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
9. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
10. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma.
Fukuhara H; Martuza RL; Rabkin SD; Ito Y; Todo T
Clin Cancer Res; 2005 Nov; 11(21):7886-90. PubMed ID: 16278413
[TBL] [Abstract][Full Text] [Related]
12. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
13. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model.
Ji X; Zhang J; Cheng L; Wei F; Li H; Liu X; Chen X; Li C; Wang Y; Huang Q
Exp Eye Res; 2009 Aug; 89(2):193-9. PubMed ID: 19328781
[TBL] [Abstract][Full Text] [Related]
15. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
Kuroda T; Rabkin SD; Martuza RL
Cancer Res; 2006 Oct; 66(20):10127-35. PubMed ID: 17047077
[TBL] [Abstract][Full Text] [Related]
16. Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Martuza RL; Rabkin SD; Kurtz A
Mol Ther; 2006 Dec; 14(6):789-97. PubMed ID: 17045531
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
[TBL] [Abstract][Full Text] [Related]
18. Combination of a fusogenic glycoprotein, prodrug activation, and oncolytic herpes simplex virus for enhanced local tumor control.
Simpson GR; Han Z; Liu B; Wang Y; Campbell G; Coffin RS
Cancer Res; 2006 May; 66(9):4835-42. PubMed ID: 16651439
[TBL] [Abstract][Full Text] [Related]
19. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
[TBL] [Abstract][Full Text] [Related]
20. An oncolytic HSV-1 mutant expressing ICP34.5 under control of a nestin promoter increases survival of animals even when symptomatic from a brain tumor.
Kambara H; Okano H; Chiocca EA; Saeki Y
Cancer Res; 2005 Apr; 65(7):2832-9. PubMed ID: 15805284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]